Chloramphenicol Toxicity

1. Disease Information

Overview. Chloramphenicol toxicity is a group of adverse drug reactions to the broad-spectrum antibiotic chloramphenicol. It has three distinct clinical forms:

1. Dose-dependent, reversible bone-marrow suppression. This mainly affects the erythroid lineage and can cause sideroblastic anemia.
2. Idiosyncratic aplastic anemia. It is rare, usually irreversible, and can occur after any route of exposure.
3. Gray baby syndrome. It occurs in neonates and premature infants and causes cardiovascular collapse.

Other toxicities are optic and peripheral neuropathy and hemolysis in G6PD deficiency. These are [general knowledge].

Entry-level decision. The toxicity is a pharmacologic or iatrogenic entity, and it has no heritable cause. The three forms have different mechanisms and time courses. The stub queue's entry_type decision is therefore live here: - A single DISEASE entry would need pathophysiology nodes that hold for every case. That is hard, because the forms share no mechanism. - A GROUPING of three entries, or a single entry with has_subtypes, is the more defensible option. - Record the choice in notes either way.

Synonyms (general knowledge). Chloramphenicol-induced aplastic anemia, chloramphenicol-induced bone marrow depression, gray (grey) baby syndrome, gray syndrome.

Identifiers. I did not verify any. Check MeSH, ICD-10-CM (T36.2X-, adverse effect and poisoning by chloramphenicol group), and MONDO via OAK.

Data origin. The sources are aggregate: pharmacology reviews, StatPearls, case reports and case series, and population case-control studies of aplastic anemia. They are not EHR-derived.

2. Etiology

Causal factor. Exposure to chloramphenicol is the cause. Systemic routes (IV or oral) are the classic ones. Topical and ocular exposure is a minor, contested contributor to aplastic anemia (see below).

Risk factors - Prematurity and neonatal age. - Gray baby syndrome is described in premature neonates given chloramphenicol IV or orally within two days of birth. The immature liver cannot glucuronidate the drug efficiently, and the neonatal kidney cannot excrete it and its metabolites well (PMC case report and review; StatPearls). - Another summary states that immature neonatal liver cannot synthesize and recycle UDP-glucuronyltransferase efficiently. - High dose or prolonged therapy. Marrow suppression is dose-dependent and reversible [general knowledge, consistent with the JCI-era literature below]. - Hepatic or renal impairment. These reduce clearance [general knowledge]. - Aplastic anemia. It is idiosyncratic. Genetic susceptibility has been proposed but is not established. I found no verified susceptibility locus.

Aplastic anemia risk figures (from search summaries, not verified at source) - A commonly quoted risk of fatal aplastic anemia after chloramphenicol is about 1 in 20,000 to 1 in 30,000 courses, roughly 13 times the background incidence (reported in the NTP Report on Carcinogens profile results; confirm in the document). - Case-control data are weaker than the headline figure: - One study reported an adjusted OR of 8.7 (95% CI 0.87–87.93) for exposure in the previous year. - An ocular-chloramphenicol analysis found 3 cases (2.1%) and 5 controls (0.4%) exposed, with an adjusted OR of 3.77 (95% CI 0.84–16.90). - The search summary said more than 400 cases across two large population-based studies had no chloramphenicol eye-drop use. - See the Haematologica article, PMC1873671, and PMC28472. I do not know which paper reports which number, so attribute them only after reading. - Curation note. The ocular-exposure OR confidence intervals include 1, so that data does not establish risk.

Protective factors. None established. Avoiding the drug and using alternative antibiotics in neonates is prevention, not a protective factor.

Gene–environment interactions. I found no verified data. G6PD deficiency with hemolysis is a recognized pharmacogenetic interaction [general knowledge, unverified]. It would need a source before being curated.

3. Phenotypes

Frequencies are not verified. Do not enter them without a source.

• The gray-baby clinical picture comes from the PMC case report and StatPearls summaries.
• That case report reviews 19 additional published cases. Mine it for outcomes and frequencies.
• Quality-of-life data: none found.
• Optic neuritis and peripheral neuropathy occur with prolonged use [general knowledge, unverified].

4. Genetic/Molecular Information

• Causal genes. None. This is not a Mendelian disease.
• Relevant pharmacogenes (general knowledge, needs sources):
• UGT2B7 mediates chloramphenicol glucuronidation. UGT1A6 and UGT1A9 involvement is less certain.
• Developmental immaturity of UGT activity is the neonatal mechanism.
• Molecular target. The mitochondrial ribosome (mtDNA-encoded protein synthesis). The sources say chloramphenicol targets the 39S large subunit of the mitoribosome (T3DB summary; verify against a primary source).
• Epigenetic and chromosomal data. None found.
• Genetic susceptibility to aplastic anemia. Unresolved. State this as a knowledge gap, not as a gene association.

5. Environmental Information

• Exposure. Systemic chloramphenicol by IV or oral route. Topical or ocular use is controversial (see Section 2).
• Lifestyle factors. None.
• Infectious agents. None cause the toxicity. The drug is used for severe infections such as meningitis and typhoid, where alternatives are limited [general knowledge].
• ECTO term to look up. An exposure term for chloramphenicol. Run l~chloramphenicol against ECTO, and try both "anaesthetic"-style spelling variants where relevant. Re-run every search a note claims, as CLAUDE.md requires.

6. Mechanism / Pathophysiology

Causal chains

Chain A: Dose-dependent marrow suppression 1. Systemic chloramphenicol reaches hematopoietic progenitors. This is inferred from the drug's distribution [general knowledge]. 2. The drug binds the mitochondrial ribosome (39S subunit) and inhibits mitochondrial protein synthesis (T3DB summary; JCI article). 3. This depletes mtDNA-encoded respiratory-chain subunits, including cytochrome components. The JCI summary says the inhibitory effect can be explained by the drug's action on cytochrome formation by the mitochondrial protein-synthesizing system. 4. Metabolically active, rapidly dividing cells, notably the erythroid lineage, lose oxidative capacity and become cytotoxically affected. Iron utilization is impaired, which gives sideroblastic changes. The sideroblastic link is stated in the search summary as thought to be related to mitochondrial dysfunction; the detailed iron-handling steps are inferred. 5. The result is reversible erythroid-predominant marrow suppression and anemia. The reviewed source says ample evidence ties the reversible suppression to inhibition of mitochondrial protein synthesis, while the aplastic form is a separate rare complication.

Chain B: Idiosyncratic aplastic anemia (mechanism unresolved) 1. Chloramphenicol exposure occurs. 2. A susceptible host develops stem-cell injury. The mechanism is not established. Proposed routes (a toxic nitroso or nitro-reduction metabolite, or genetic susceptibility) are hypotheses, not demonstrated here. 3. Marrow aplasia and pancytopenia follow.

Do not link Chain A's mitochondrial inhibition to aplastic anemia as if causal. The sources frame them as separate complications.

Chain C: Gray baby syndrome 1. A neonate, usually premature, receives chloramphenicol. 2. Immature hepatic UDP-glucuronyltransferase activity means glucuronidation is deficient. Renal excretion is also immature (PMC). 3. Unconjugated drug accumulates to high serum concentrations. 4. Accumulated drug inhibits mitochondrial function in cardiac and other tissues. This step is the commonly proposed but not directly demonstrated link, and it needs a source before curation. 5. Cardiovascular collapse follows, with mottling, then ashen-gray skin, hypothermia, and cyanosis.

Suggested ontology terms (lookup required)

• GO. Mitochondrial translation. Also consider a mitochondrial ribosome-related term for the molecular function (peptidyl transferase activity, inhibited by drug). Check the exact labels.
• CL. Erythroid progenitor cell, hematopoietic stem cell, hepatocyte (glucuronidation).
• CHEBI. Chloramphenicol. Look it up, and also look up chloramphenicol glucuronide if a metabolite node is wanted.
• GO Cellular Component. Mitochondrion, mitochondrial large ribosomal subunit.
• Modifier. Use DECREASED for mitochondrial translation (a quantitative state). Do not use LOSS_OF_FUNCTION unless you can justify it qualitatively.
• Biological scale tags. MOLECULAR for ribosome inhibition, CELLULAR for erythroid suppression, ORGANISM for circulatory collapse.

Mechanism module candidates

kb/modules/ already has antimicrobial drug mechanism modules and a "treatment toxicity / side effect as mechanism" family. Run just list-modules ribosom and just list-modules mitochond and use rg -il "mitochondrial translation" kb/modules before writing new nodes.

Molecular profiling, single-cell, and screens

No data found for chloramphenicol toxicity. State "not available".

7. Anatomical Structures Affected

• Primary. Bone marrow, especially the erythroid compartment. Also the circulatory system in neonates.
• Secondary. Liver (site of drug metabolism). Optic nerve and peripheral nerves with chronic use [general knowledge, unverified].
• Cells. Erythroid progenitors, hematopoietic stem cells, hepatocytes, cardiomyocytes (proposed).
• Subcellular. Mitochondria and the mitoribosome.
• Laterality. Not applicable, since the effects are systemic.
• UBERON terms. Look up bone marrow, liver, and optic nerve.

8. Temporal Development

• Marrow suppression. It develops during therapy, is dose-related, and is generally reversible after withdrawal.
• Aplastic anemia. It can appear weeks to months after exposure, is idiosyncratic, and is often irreversible. The delay is [general knowledge]; confirm it.
• Gray baby syndrome. It typically appears within the first days of therapy in neonates.
• Critical period. The neonatal and premature period, when glucuronidation is immature.
• Remission. Marrow suppression reverses on withdrawal. For aplastic anemia I have no verified remission data.

9. Inheritance and Population

• Inheritance. None.
• Incidence figures.
• Aplastic anemia risk after chloramphenicol was quoted at about 1 in 20,000 to 1 in 30,000, as above.
• A separate figure for background aplastic anemia incidence in Latin American countries was 1.6 per million per year, from a search summary. This is background incidence, not toxicity incidence.
• If you encode Prevalence, use measure_type: UNKNOWN or a literature-based measure, not a rate you cannot quote. Gray baby syndrome today is rare, but I have no verified figure.
• Demographics. Neonates and premature infants for gray baby syndrome. No verified sex ratio or geography.
• Consanguinity, founder effects, anticipation, carrier frequency. Not applicable.

10. Diagnostics

All of this section is [general knowledge] unless stated. Verify with StatPearls (Gray baby syndrome and chloramphenicol chapters) and clinical guidelines.

• Clinical diagnosis. Temporal association with drug exposure plus compatible findings.
• Laboratory tests.
• CBC with reticulocyte count. Suppression usually shows reticulocytopenia and anemia.
• Marrow examination for vacuolated precursors, or aplasia in the idiosyncratic form.
• Serum drug concentration monitoring. Therapeutic ranges exist, and high levels predict toxicity. Get the numbers from a guideline, not memory.
• Genetic testing. Not applicable.
• Differential. Neonatal sepsis and shock, other drug-induced marrow failure, and other causes of aplastic anemia.
• Screening. Monitoring blood counts during therapy. Therapeutic drug monitoring in neonates.

11. Outcome/Prognosis

• Marrow suppression. Reversible on drug withdrawal.
• Aplastic anemia. Mortality is high. The risk is much rarer than the older literature implied, as the case-control summaries above suggest.
• Gray baby syndrome. It is potentially fatal. The PMC case report with 19 reviewed cases is the best lead for mortality figures. I could not read them.
• Prognostic factors. Early recognition and drug cessation, serum level, and gestational age [general knowledge].

12. Treatment

All of this is [general knowledge]. Confirm each item against a cited source before entering a treatments: block.

• Stop chloramphenicol. This is the primary treatment.
• Supportive care. Circulatory and respiratory support for gray baby syndrome. Transfusion for marrow suppression.
• Removal of the drug. Exchange transfusion, charcoal hemoperfusion, and hemodialysis have been reported in gray baby syndrome. Check the case-report literature for the actual evidence level.
• Aplastic anemia. Standard management is immunosuppressive therapy or hematopoietic stem cell transplantation. This is not specific to chloramphenicol, so reference the general aplastic anemia entry if one exists.
• Experimental or trial data. None found. Run a ClinicalTrials.gov search before writing "none".
• NCIT terms to look up. Supportive care, blood transfusion, hematopoietic cell transplantation, and discontinuation of therapy if NCIT has it. Apply the modality rules in CLAUDE.md. For example, NCIT:C15431 maps to CELL_THERAPY in the mechanical backfill table, and I have not checked that mapping against the ontology in this session.

13. Prevention

• Primary prevention. Avoid chloramphenicol in neonates, or where alternatives exist. This is the key lesson from gray baby syndrome.
• Dose control. Use serum level monitoring and dose adjustment in neonates and in hepatic or renal impairment [general knowledge].
• Secondary prevention. Serial blood counts.
• Public health. Regulatory restrictions and label warnings. I did not verify jurisdiction-specific policy.
• Vaccines and genetic counseling. Not applicable.

14. Other Species / Natural Disease

• Veterinary use and toxicity. One search result was a veterinary journal PDF (Eurasian J Vet Sci). I did not read it. It suggests animal-toxicity literature exists.
• Cats. They are known for deficient glucuronidation and are sensitive to some drugs [general knowledge]. Whether chloramphenicol toxicity is documented in cats is unverified.
• Food-producing animals. Chloramphenicol is banned in food animals in many jurisdictions. This is a regulatory point, not a verified toxicity statement.
• NCBI Taxon, breed, and OMIA entries. None applicable (not heritable).
• Zoonosis. Not applicable.

15. Model Organisms

• Mitochondrial translation inhibition. The mechanism has been demonstrated in mammalian systems in the JCI-era literature (JCI). The search summary does not say which species. Read it before assigning evidence_source.
• Cell models. Bone marrow cell and cell-line studies of mitochondrial protein synthesis inhibition are plausible leads. I have no verified citation.
• Genetic models. None. Mouse and zebrafish models of chloramphenicol-induced marrow suppression or gray baby syndrome: not found.
• Limitations. Reversible suppression is modeled by mitochondrial translation inhibition, but idiosyncratic aplastic anemia has no known model.
• Databases. MGI, ZFIN and IMPC are not applicable because the cause is non-genetic.

Curation Next Steps

1. Resolve the MONDO ID and the lump/split decision (Section 1).
2. Fetch references. Run just fetch-reference on the PMC articles (PMC12833000, PMC1873671, PMC28472), the JCI article, and the Haematologica article. Get PMIDs from the fetched cache files, not from memory.
3. Look up every ontology term. Use OAK or the caches, in the same step as writing the CURIE. The dismech-terms skill governs this.
4. Assign evidence_source correctly.
5. Human case series: HUMAN_CLINICAL.
6. Mitochondrial ribosome studies in cells or isolated mitochondria: IN_VITRO.
7. Studies in animals: MODEL_ORGANISM.
8. Mark unverified links as gaps. Use KNOWLEDGE_GAP discussions for the aplastic anemia mechanism and for the cardiac step of gray baby syndrome. Do not state them as causal edges.
9. Add a history/ record with just new-history.

Sources

• Chloramphenicol-induced gray baby syndrome: case report and review (PMC12833000)
• StatPearls: Gray baby syndrome
• Frontiers in Pediatrics 2025 article (10.3389/fped.2025.1733059)
• JCI article 107015
• T3DB chloramphenicol record
• NTP Report on Carcinogens: chloramphenicol profile
• Haematologica article 5343
• PMC1873671
• PMC28472
• Eurasian J Vet Sci PDF